Page last updated: 2024-10-26

etidronate and Hematologic Neoplasms

etidronate has been researched along with Hematologic Neoplasms in 2 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Research Excerpts

Excerpt	Relevance	Reference
"Specific treatment of cancer remains essential to prevent TIH relapse."	2.41	[Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Tauchmanovà, L	1
Selleri, C	1
Esposito, M	1
Di Somma, C	1
Orio, F	1
Bifulco, G	1
Palomba, S	1
Lombardi, G	1
Rotoli, B	1
Colao, A	1
Lortholary, A	1

Reviews

1 review available for etidronate and Hematologic Neoplasms

Article	Year
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. La Revue de medecine interne, 2001, Volume: 22, Issue:7 Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog	2001

Trials

1 trial available for etidronate and Hematologic Neoplasms

Article	Year
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:12 Topics: Administration, Oral; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administr	2003

Article

Year

Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:12

Topics: Administration, Oral; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administr

2003